281 related articles for article (PubMed ID: 20600570)
1. Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.
Yu YZ; Zhang SM; Wang WB; Du Y; Zhu HQ; Wang RL; Zhou XW; Lin JB; Wang S; Yu WY; Huang PT; Sun ZW
Biochimie; 2010 Oct; 92(10):1315-20. PubMed ID: 20600570
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX
Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
[TBL] [Abstract][Full Text] [Related]
5. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins.
Barash JR; Arnon SS
J Infect Dis; 2014 Jan; 209(2):183-91. PubMed ID: 24106296
[TBL] [Abstract][Full Text] [Related]
6. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice.
Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X
Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963
[TBL] [Abstract][Full Text] [Related]
7. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW
Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829
[TBL] [Abstract][Full Text] [Related]
9. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
10. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays.
Jones RG; Alsop TA; Hull R; Tierney R; Rigsby P; Holley J; Sesardic D
Toxicon; 2006 Sep; 48(3):246-54. PubMed ID: 16870221
[TBL] [Abstract][Full Text] [Related]
11. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.
Atassi MZ; Dolimbek BZ; Hayakari M; Middlebrook JL; Whitney B; Oshima M
J Protein Chem; 1996 Oct; 15(7):691-700. PubMed ID: 8968960
[TBL] [Abstract][Full Text] [Related]
12. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate.
Yu YZ; Li N; Zhu HQ; Wang RL; Du Y; Wang S; Yu WY; Sun ZW
Vaccine; 2009 May; 27(21):2816-22. PubMed ID: 19428892
[TBL] [Abstract][Full Text] [Related]
13. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
14. Exposure-Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product.
Beliveau M; Anderson D; Barker D; Kodihalli S; Simard E; Hall C; Richardson JS
Clin Pharmacol Ther; 2022 Jul; 112(1):171-180. PubMed ID: 35467014
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
[TBL] [Abstract][Full Text] [Related]
16. Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1.
Kim NY; Park KE; Lee YJ; Kim YM; Hong SH; Son WR; Hong S; Lee S; Ahn HB; Yang J; Seo JP; Lim YK; Yu CH; Hur GH; Jeong ST; Lee HS; Song K; Kang TJ; Shin YK; Choi JS; Choi JY
J Microbiol Biotechnol; 2019 Jul; 29(7):1165-1176. PubMed ID: 31280529
[TBL] [Abstract][Full Text] [Related]
17. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of equine botulism antitoxin in Rhesus macaques.
Kodihalli S; Emanuel A; Takla T; Hua Y; Hobbs C; LeClaire R; O'Donnell DC
PLoS One; 2017; 12(11):e0186892. PubMed ID: 29166654
[TBL] [Abstract][Full Text] [Related]
19. Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt.
Hibbs RG; Weber JT; Corwin A; Allos BM; Abd el Rehim MS; Sharkawy SE; Sarn JE; McKee KT
Clin Infect Dis; 1996 Aug; 23(2):337-40. PubMed ID: 8842274
[TBL] [Abstract][Full Text] [Related]
20. A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.
Maslanka SE; Lúquez C; Dykes JK; Tepp WH; Pier CL; Pellett S; Raphael BH; Kalb SR; Barr JR; Rao A; Johnson EA
J Infect Dis; 2016 Feb; 213(3):379-85. PubMed ID: 26068781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
